SynthesisFrontiers in cardiovascular medicine2026
Serum resistin as a potential biomarker for stratifying the severity of coronary heart disease: a network meta-analysis.
Synthesis in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically quantify the graded relationship between serum resistin levels and the severity of coronary heart disease (CHD) using a network meta-analysis, thereby evaluating its potential as a biological marker of disease progression. Methods: We conducted a comprehensive search of major international and Chinese databases up to December 2025. A random-effects network meta-analysis was performed to calculate standardized mean differences (SMD) and Surface Under the Cumulative Ranking (SUCRA) values. Subgroup, sensitivity, and Trim-and-Fill analyses were conducted to investigate heterogeneity and publication bias. Results: A total of 26 studies ( Conclusion: Serum resistin levels show a clear, graded association with CHD severity, positioning resistin as a potent biological correlate of the underlying inflammatory burden. However, due to significant heterogeneity and publication bias that likely inflate the observed effect sizes, resistin is not suitable as a standalone diagnostic tool. Its potential clinical utility may lie as an adjunctive marker in multi-biomarker models for risk stratification, a role that requires validation in large-scale prospective studies using standardized assays. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, PROSPERO CRD420261397089.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.